Direct oral anticoagulants are increasingly used on patients with atrial fibrillation for the prevention of stroke and systemic embolism. A significant proportion of patients with atrial fibrillation have or will develop concomitant ischaemic heart disease. The choice of the most appropriate antithrombotic treatment strategy in this setting can be challenging due to the concurrent risk of ischaemic and haemorrhagic complications.
- Understand the mechanism of action and treatment indications of direct oral anticoagulants in patients with concomitant atrial fibrillation and ischaemic heart disease;
- Understand the implications of study design on interpretation of RCT in this field; and
- Apply the acquired knowledge in clinical practice.